Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions Anwar R. Padhani, Jeffrey Weinreb, Andrew.

Slides:

Advertisements

Similar presentations

V. Scattoni mpMRI of the prostate: Does it change indications for biopsy and repeat biopsy?

Advertisements

Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.

Volume 59, Issue 2, Pages (February 2011)

The PSA Era is not Over for Prostate Cancer

Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate.

Volume 71, Issue 6, Pages (June 2017)

Volume 69, Issue 1, Pages (January 2016)

Volume 64, Issue 6, Pages (December 2013)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Breast, prostate, and thyroid cancer screening tests and overdiagnosis

Volume 59, Issue 1, Pages (January 2011)

Testosterone Therapy in Men With Prostate Cancer

Volume 56, Issue 6, Pages (December 2009)

Volume 72, Issue 6, Pages (December 2017)

Volume 52, Issue 1, Pages (July 2007)

Volume 67, Issue 3, Pages (March 2015)

European Urology Oncology

Volume 64, Issue 6, Pages (December 2013)

Figure 3 Semantic model of the active surveillance (AS) timeline

Volume 71, Issue 5, Pages (May 2017)

Prostate Cancer Epidemic in Sight?

Volume 65, Issue 6, Pages (June 2014)

Volume 66, Issue 1, Pages (July 2014)

Volume 59, Issue 2, Pages (February 2011)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 68, Issue 5, Pages (November 2015)

MP57-17 CAN PROSTATIC SPECIFIC ANTIGEN VELOCITY (PSAV) IMPROVE THE DIAGNOSTIC ACCURACY OF PROSTATE IMAGING REPORTING AND DATA SYSTEM (PI-RADS) SCORE.

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 54, Issue 5, Pages (November 2008)

Volume 68, Issue 3, Pages (September 2015)

Volume 56, Issue 2, Pages (August 2009)

Volume 62, Issue 1, Pages (July 2012)

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 63, Issue 3, Pages (March 2013)

Volume 71, Issue 4, Pages (April 2017)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer Valeria.

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 67, Issue 6, Pages (June 2015)

Volume 65, Issue 4, Pages (April 2014)

Volume 68, Issue 6, Pages (December 2015)

Volume 66, Issue 3, Pages (September 2014)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

European Urology Oncology

European Urology Oncology

Volume 53, Issue 1, Pages (January 2008)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 75, Issue 4, Pages (April 2019)

Volume 59, Issue 4, Pages (April 2011)

Volume 73, Issue 1, Pages (January 2018)

Volume 65, Issue 3, Pages (March 2014)

Volume 75, Issue 4, Pages (April 2019)

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Prostate Cancer Update

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection.

Oncoforum Urology: Prostate Cancer 2008 at a Glance

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

Prostate cancer screening beyond PSA – STHLM3 and/or MRI

Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood Jan F.M. Verbeek,

European Urology Oncology

Presentation transcript:

Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions Anwar R. Padhani, Jeffrey Weinreb, Andrew B. Rosenkrantz, Geert Villeirs, Baris Turkbey, Jelle Barentsz European Urology DOI: 10.1016/j.eururo.2018.05.035 Copyright © 2018 The Author(s) Terms and Conditions

Fig. 1 Prostate cancer diagnostic pathway: benefits of incorporating mpMRI, PI-RADS scoring and MRDB sampling. (1) Greater precision in determining tumor grade and volume (improved risk stratification and higher precision in making therapy choices). (2) Potential higher rates of detection of clinically significant disease needing active treatments. (3) Potential reductions in diagnosis of indolent disease, thereby reducing overdiagnosis and overtreatment. (4) Fewer targeted biopsies per patient required to make effective diagnoses and minimization of biopsy-related morbidity. (5) Reduction in the number of patients undergoing biopsy. mpMRI=multiparametric magnetic resonance imaging; PI-RADS=Prostate Imaging-Reporting and Data System; MRDB=magnetic resonance–directed biopsy; MDT=multidisciplinary team; PSAD=prostate-specific antigen density. European Urology DOI: (10.1016/j.eururo.2018.05.035) Copyright © 2018 The Author(s) Terms and Conditions